Most Read Articles

The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax (Nuvaxovid). The new formulations are indicated for use in all adults ≥65 years old and in persons 6 months (Spikevax), 5 years (Comirnaty), or 12 years (mNEXSPIKE, Nuvaxovid) through 64 years old who are at high risk for severe COVID-19 because of an underlying condition. An Emergency Use Authorization allowing administration of the Pfizer vaccine to children 6 months through 4 years old has been withdrawn.

Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis

View the Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis

Nexplanon, a single-rod contraceptive implant containing the progestin etonogestrel, has now been approved for prevention of pregnancy for up to 5 years. It was previously approved for up to 3 years of use.

Our recent article entitled Lumateperone (Caplyta) for Adjunctive Treatment of Depression should have included urinary incontinence among the adverse effects associated with use of second-generation antipsychotic drugs. Urinary incontinence has been reported with both first- and second-generation antipsychotics. Possible causes include the anti-alpha-adrenergic, antidopaminergic, and anticholinergic effects of these drugs, as well as sedation. In an observational study in 200 women 20-40 years old, urinary incontinence was reported by 29% of those taking antipsychotic drugs and by 13% of age-matched controls.

The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix, is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.

In our article titled A Renal Indication for Semaglutide (Ozempic) (Med Lett Drugs Ther 2025; 67:38), the MACE endpoint defined in Table 2, footnote 3 was incorrectly stated as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or all-cause mortality. All-cause mortality should not have been included in the composite endpoint.

The FDA has approved two antibiotics, gepotidacin (Blujepa — GSK) and zoliflodacin (Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old. Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females. Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.